ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0298

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study

Derek Haaland1, Jonathan Chan2, Larissa Lisnevskaia3, Andrew Chow4, Tanya Girard5, Pierre-André Fournier5 and Louis Bessette6, 1The Waterside Clinic, Oro Medonte, ON, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Oshawa Clinic, Oshawa, ON, Canada, 4Credit Valley Rheumatology, University of Toronto, Mississauga, ON, Canada, 5AbbVie, Saint-Laurent, QC, Canada, 6Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada

Meeting: ACR Convergence 2022

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)- inhibitor that has been shown to be effective and well-tolerated in patients with rheumatoid arthritis (RA) in the Phase 3 SELECT clinical trials and was approved in Canada as a treatment option for RA in December 2019. The Canadian Real-Life post-marketing Observational Study assessing the Effectiveness of UPadacitinib for treating rheumatoid arthritis (CLOSE-UP) study initiated in 2020 aims to investigate the effectiveness of UPA across 390 Canadians including csDMARD, bDMARD and tsDMARD experienced real-world RA patients.

Methods: CLOSE-UP is an ongoing, prospective, multicenter, observational post-marketing study in adults with moderate-to-severe RA who are treated with UPA 15 mg once daily, with the decision to initiate UPA made prior to study participation. Participants are followed for 24 months following UPA initiation with data collected at routine clinic visits. The primary endpoint is the proportion of participants achieving a Disease Activity Score – 28 Joint Count, C-reactive protein (DAS28-CRP) < 2.6 at 6 months. Secondary endpoints include, pain score using a visual analog scale, fatigue (FACIT-F), physical function as measured by the Health Assessment Questionnaire (HAQ) and other assessments of disease activity including Clinical Disease Activity Index (CDAI) score. Per protocol, eligible subjects are grouped by prior/most recent exposure to: no b/tsDMARDs (bio-naïve); ≤2 bDMARDs but no tsDMARD (bio-experienced), and ≤1 bDMARD followed by a tsDMARD (tsDMARD-experienced). This descriptive interim analysis reports data for participants who had completed their 6-month visit by March 18, 2022. Data are presented as observed and summarized descriptively, with no statistical analyses conducted.

Results: Of the 183 participants included in this interim analysis, 89 (49%) were bio-naïve, 69 (38%) were bio-experienced and 25 (14%) were tsDMARD-experienced (Table 1). Overall, 63% of patients achieved a DAS28-CRP < 2.6 (primary endpoint; Figure 1) The proportion of participants achieving DAS28-CRP < 2.6 at the 6-month visit was similar between those receiving UPA monotherapy (62.2%, n=69/111) and those receiving UPA in combination with a csDMARD (63.9%, n=36/45). Physical function and patient reported outcomes including pain and fatigue improved over the first 6 months following UPA initiation. The safety profile of UPA was consistent with that seen in Phase 3 trials with no new safety signals (Table 2).

Conclusion: Consistent with clinical trial data, interim analysis of this real-world Canadian study showed that disease activity was reduced, and patient reported outcomes improved with an overall favorable benefit:risk profile for Canadian patients receiving UPA in the real-world setting.

Supporting image 1

1. Has not been previously exposed to any bDMARD or tsDMARD.
2. Has not been previously exposed to tsDMARD and has been previously exposed to ≤2 bDMARDs.
3. Has been previously treated with one tsDMARD and ≤1 bDMARD prior to treatment with that tsDMARD.
For readability, parameters with no missing data do not have patient numbers specified. Cardiovascular risk factors include Smoking, BMI>=30, hypertension, diabetes, atherosclerosis, ischemic heart disease.
APCA, anti-citrullinated protein antibody; b, biologic; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; cs, conventional synthetic; DAS28, Disease Activity Score – 28 Joint Count; DMARD, disease modifying antirheumatic drug; FACIT-F, Functional Assessment of Chronic Illness Therapy – Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; RF, rheumatoid factor; TJC, tender joint count; ts, targeted synthetic; SJC, swollen joint count; VAS, visual analog scale.

Supporting image 2

Bio-naïve: has not been previously exposed to any bDMARD or tsDMARD. Bio-experienced: has not been previously exposed to tsDMARD and has been previously exposed to ≤2 bDMARDs. tsDMARD-experienced: has been previously treated with one tsDMARD and ≤1 bDMARD prior to treatment with that tsDMARD. % is based on number of subjects with available data at each visit within the group. DAS28-CRP remission: score <2.8; LDA: score ≤3.2. b, biologic; CRP, C-reactive protein; cs, conventional synthetic; DAS28, Disease Activity Score – 28 Joint Count; DMARD, disease modifying antirheumatic drug; LDA, low disease activity; ts, targeted synthetic.

Supporting image 3

Adverse Events (AEs) are coded using MedDRA Version 23.1. AEs of special interest include zoster, MACE, VTE, infections, serious infections, malignancy (excluding NMSC), death. MACE, Major Adverse Cardiac Event; NMSC, Non Melanoma Skin Cancer; SAE, Serious AE; VTE, Venous Thromboembolism.


Disclosures: D. Haaland, AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, Merck/MSD, UCB, Celgene, Adiga Life-Sciences, Can-Fite Biopharma, Regeneron, Gilead; J. Chan, AbbVie; L. Lisnevskaia, AbbVie; A. Chow, AbbVie, Celltrion, Pfizer, Novartis; T. Girard, AbbVie; P. Fournier, AbbVie; L. Bessette, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Genzyme, UCB, Gilead, Merck/MSD, Organon, Roche.

To cite this abstract in AMA style:

Haaland D, Chan J, Lisnevskaia L, Chow A, Girard T, Fournier P, Bessette L. Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effectiveness-of-upadacitinib-in-patients-with-rheumatoid-arthritis-in-canadian-real-world-practice-interim-results-from-the-close-up-post-marketing-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-upadacitinib-in-patients-with-rheumatoid-arthritis-in-canadian-real-world-practice-interim-results-from-the-close-up-post-marketing-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology